PDCD1 and head and neck squamous cell carcinoma: Despite progresses achieved in therapies, such as using nivolumab and pembrolizumab to target the programmed cell death protein 1 (PD-1) in advanced HNSCC, the overall 5-year survival rate for patients with HNSCC remains unsatisfactory, which is below 50%.